Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Roche Posts Flat Nine-Month Sales

By Pharmaceutical Processing | October 16, 2014

GENEVA (AP) — Swiss drugmaker Roche Holding AG posted flat sales for the first nine months of 2014, but said Thursday the results show strong demand for its cancer drugs and emerging new products.

The Basel, Switzerland-based company’s group sales were reported at 34.8 billion Swiss francs, nearly unchanged from 34.9 billion francs in the same period last year. But when measured in constant exchange rates, sales rose 5 percent over the first three quarters of the year.

It noted that a number of currencies, notably the U.S. dollar, remained weaker against the Swiss franc throughout the year.

The world’s biggest producer of cancer-fighting drugs said its sales of cancer medicines Herceptin, Perjeta and Kadcyla together increased 21 percent, while its sales of rheumatoid arthritis treatment Actemra/RoActemra rose 24 percent.

For the nine months, measured in constant exchange rates, it said sales were 4 percent higher in its pharmaceuticals division and 6 percent higher in its diagnostics division.

For the third quarter, Roche’s sales increased 1.8 percent from the similar period a year ago. The company posted sales of 11.78 billion francs for July to September, up from 11.57 billion francs a year earlier.

“Demand for our products is strong in both divisions and we are well on track to reach our full-year targets,” CEO Severin Schwan said of the company’s expectation for low- to mid-single-digit growth in group sales for the full year at constant exchange rates.

Earlier this month, the company gained U.S. approval for Esbriet, which Roche said could make “a considerable difference” in the treatment of patients with a debilitating lung disease, idiopathic pulmonary fibrosis.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE